News Centre

VASTox announces the initiation of a fourth proprietary drug discovery programme focused on the bone morphogenetic protein (BMP) signaling pathway.

VASTox plc announces the appointment of Sir Brian Richards CBE to the Board of VASTox as a Non-Executive Director.

VASTox announces today that it has initiated a new drug discovery programme focused on the treatment of Spinal Muscular Atrophy (SMA), a genetic neuromuscular disease.

VASTox announces that it has signed two new agreements in the field of drug development services and chemical genomics.

VASTox announces that all of the resolutions at the AGM of the Company, held today, were duly passed.

VASTox plc (AIM: VOX), the drug discovery and chemical genomics company, today announces its audited preliminary results for the year ended 31 January 2005.

Professor Kay Davies FRS, CBE, presents a scientific breakthrough in new research, in the field of muscular dystrophy, to the Oxford Innovation Society.

VASTox appoints three new members to its Scientific Advisory Board. They include Professor Francesco Muntoni, Professor Roger Patient and Dr Marcel van den Heuvel.

VASTox announces that it has signed a contract with an undisclosed European biotech company in the area of targeting of drugs to specific organs and cell types through the use of sugars.

VASTox announces a chemical genomics screening deal with MNLpharma (formerly Molecular Nature).